Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 19/20 | 0.62 |
| ▸ | PDE4A known ✓ | P27815 | 3/20 | 0.62 |
| ▸ | PDE4C known ✓ | Q08493 | 3/20 | 0.62 |
| ▸ | PDE4D known ✓ | Q08499 | 3/20 | 0.62 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.52 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324140 | 0.99 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| Hydrochloric Acid SCHEMBL183829 | 0.88 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| SCHEMBL184710 | 0.87 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| SCHEMBL185012 | 0.83 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL184411 | 0.83 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| SCHEMBL2328039 | 0.82 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| Hydrochloric Acid SCHEMBL27933193 | 0.81 | PDE4A (0.49) | PDE4BPDE4APDE4CPDE4DMAP4K3 | |
| Hydrochloric Acid SCHEMBL2330661 | 0.81 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DDNMT3A | |
| SCHEMBL184320 | 0.81 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2327036 | 0.80 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DDNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-9090597-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2508520-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2402330-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885 |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE5A | PDE4B 2/4885PDE4A 1/4885PDE4C 8/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDE4B 4/4885PDE4A 1/4885PDE4C 9/4885 |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4A 1/4885PDE4C 5/4885 |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDE4B 4/4885PDE4A 1/4885PDE4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.